All In Biotech

Drug Trial Radar · NCT04412577

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3473 Tablets

Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

57

Planned (sponsor's estimate)

Start

Oct 12, 2020

Primary completion

Dec 2021

Study completion Jun 2022

Sponsor

Sponsor type
Industry
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the maximum tolerated dose (MTD), occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3473 tablets in Chinese adult patients with Relapsed or refractory hematological malignancies.

Conditions

  • Relapsed/Refractory Hematological Malignancies

Interventions

  • TQB3473Drug

    TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: up to 31 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.